Scholarlink

Purpose <p>Surgical extent for isthmus papillary thyroid carcinoma (PTC) remains debated. We evaluated the survival outcomes of thyroid isthmusectomy (TI).</p> Methods <p>PTC patients undergoing TI were identified from the Surveillance, Epidemiology, and End Results database. Overall survival (OS), disease-specific survival (DSS), and prognostic factors were analyzed. Survival outcomes of TI were compared with thyroid lobectomy (TL) and total thyroidectomy (TT) via propensity score matching (PSM).</p> Results <p>Among 308 TI patients, 10-year OS and DSS were 89.5% and 100.0%. Male sex, age ≥ 55 years, and T3–4 category were independent risk factors for poorer OS. After PSM, TI demonstrated comparable OS to TL (<i>P</i> = 0.80) and TT (<i>P</i> = 0.59). However, TT yielded superior OS in subgroups with T3–4 tumors, tumor size &gt; 2cm, lymph node metastasis, and age ≥ 55 years.</p> Conclusion <p>TI might be an oncologically safe option for younger patients with solitary isthmus PTC (cT1N0M0).</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Survival outcomes following isthmusectomy versus lobectomy and total thyroidectomy for papillary thyroid carcinoma: A propensity score-matched study

  • 期刊论文

  • 发表日期：

    2026年4月23日

查看全文
  • Shangcheng Yan,
  • Zhen Cao,
  • Qiyao Zhang,
  • Bingrong Chen,
  • Bohan Huang,
  • Yuqian Kan,
  • Xinwei Cui,
  • Ziwen Liu

摘要

Purpose

Surgical extent for isthmus papillary thyroid carcinoma (PTC) remains debated. We evaluated the survival outcomes of thyroid isthmusectomy (TI).

Methods

PTC patients undergoing TI were identified from the Surveillance, Epidemiology, and End Results database. Overall survival (OS), disease-specific survival (DSS), and prognostic factors were analyzed. Survival outcomes of TI were compared with thyroid lobectomy (TL) and total thyroidectomy (TT) via propensity score matching (PSM).

Results

Among 308 TI patients, 10-year OS and DSS were 89.5% and 100.0%. Male sex, age ≥ 55 years, and T3–4 category were independent risk factors for poorer OS. After PSM, TI demonstrated comparable OS to TL (P = 0.80) and TT (P = 0.59). However, TT yielded superior OS in subgroups with T3–4 tumors, tumor size > 2cm, lymph node metastasis, and age ≥ 55 years.

Conclusion

TI might be an oncologically safe option for younger patients with solitary isthmus PTC (cT1N0M0).